对付癌症: 治是不治，不治是治
|| 推荐到群组
如何对付癌症？“治是不治，不治是治，夫唯不治，天下莫能与之治”。
老同学感到遗憾：他的父亲因患癌症的治疗。他的父亲，70岁，农民，治疗前可以肩按住天然气罐到7楼。当诊断，老人的预测6个月至12个月的生命。他的父亲不想痛任何手术，因为他说他得到了很好的生活，不希望任何痛苦的手术和治疗。所有成功的孩子无法接受不治疗他们的父亲。老人通过规范的治疗：手术，放疗和化疗，在五个月内死于癌症。
另一个同村70 +岁老人，没钱负担手术放疗和化疗，家里等待死。这老头诊断五年后现仍然活着。
怎么回事？我不知道，因为我觉得它总是个人 - 你不能这些个别案例得出任何结论。我一直在思考与了解许多癌症患者的治疗之旅：什么是最好的解决方案？我不知道答案。你呢？有一些想法和故事的患者如下。
“不自见，故明；不自是，故彰；不自伐，故有功；不自矜；故长；夫唯不争，故天下莫能与之争。”语出自《老子》。
意思是说：不显示自己，不自以为是，因而更显耀突出；不夸耀自己，因而有功绩；不自以为贤能，因而受到尊重；只有那不与人相争的，世界上没有人能和他相争。
“争是不争，不争是争，夫唯不争，天下莫能与之争”。
“夫唯不争，故天下莫能与之争。”其实是自相矛盾的一句话，无争故莫之争，意思与佛经的如来寂灭众生，其实并未寂灭众生是一个道理，世界上别人唯一不能和你争的就是你的心，只有你自己才能渡自己，只要你不愿意，如来也不能寂灭你，对自己心毫无矫揉造作，对私心，贪念以自然流逝的心态对待，这就是与心无争，
自在圆满，没有了杂念，自然天下莫能与之争。
人道有善恶，天道无善恶
天地万物恒为“大"者为天道！生老病死，春去冬来自然之理也，天道即是自然，既然是自然有何须分个善恶呢？
人道只是天道中的一道，回归天道，得到天道的大仁、大智，最寻天人合一、物我相忘的理想境界便是天命！
如何对付癌症？
“治是不治，不治是治，夫唯不治，天下莫能与之治”。
“我们可能会反应过度对癌细胞”，“中
入侵的外星人“，”这导致过度治疗和伤害我们
自己的身体用激进的多模式（手术，
辐射和化学疗法）[8]。也许，我们应该
考虑到肿瘤细胞有着相似的公民，要求
地球上的生存，因为他们的生存
是由它们的演化的驱动力驱动的[9]。维持
生物多样性和异质性可能平衡的有机体或
器官出了充满敌意的环境[10,11]。因此，
管理肿瘤生长，而不是消除它应该是
用于治疗肿瘤的新指导方针。刨除癌症
治疗驱动生产的人群耐药
肿瘤细胞在消除对药物敏感的细胞，而
管理肿瘤生长来治疗肿瘤的最小
药物的剂量，以便调节一些药敏的生存
细胞[12,13]。这种治疗模式可以帮助
对药物敏感的细胞外竞争抗病品种
药物治疗后，从而保持肿瘤存活
但小的，可管理的[1,14]。
''保持肿瘤活着，但小的，可管理的'声音
合理的策略。但是，我们如何管理肿瘤
增长，而不是消灭它？我们认为，管理SSS
可能是一种有效的策略。（干细胞与发育
21卷4，2012年，503-506页。玛丽安力博特公司DOI：10.1089 /scd.2011.0267）。
~~
English version of original thoughts:
Former classmate regrets: his father died of cancertreatment. His father, over 70 year old, farmer , could shoulder-hold a tank ofnatural gas up to 7 floor before treatment. When diagnosed, the old man'spredicted for 6-month to 12-month life. His father didn’t want any surgery ofpain as he said he got good life and didn’t want any painful surgery andtreatment. All children, however, are so successful that they couldn't acceptno-treatment for their father. The old man got through standard treatment:surgery, radiation and chemotherapy, died of cancer in five months.
Another old man of 70+-year-old in the same village, was sopoor to afford any surgery, radiation and chemotherapy, waiting to die at home.This old man still lives now after five years of diagnosis.
What happens? I don’t know as I thought it’s always personal– you can’t draw any conclusion out of these individual cases. I’ve been thinkingas knowing many cancer patients’ journey of treatment: What’s the bestsolution? I don’t know the answer. How about you? Some thoughts and patientsstory are as follows.
How to deal with cancer?
“We may over-reacttoward cancer cells, ‘‘the
invading aliens,’’which lead to over-treating and injure our
own body by usingaggressive multi-modalities (surgery,
radiation, andchemotherapies) [8]. Perhaps, we ought to
consider thatcancer cells share similar citizenship, demanding
to survive on theEarth because their survivorship
is driven by theirevolutional driving force [9]. Sustaining the
biodiversity andheterogeneity may balance organisms or
organs out of thehostile environment [10,11]. As such,
managing tumorgrowth rather than eliminating it should be
a new guideline fortreating tumors. The eliminating-cancer
treatments driveproducing populations of drug-resistant
tumor cells uponeliminating the drug-sensitive cells while
managing tumorgrowth to treat tumors with minimum
doses of drug so asto modulate the survival of some drugsensitive
cells [12,13]. Thistreatment paradigm may help the
drug-sensitivecells out-compete the resistant ones upon
completion of drugtreatment, thereby keeping tumors alive
but small and manageable[1,14].
‘‘Keepingtumors alive but small and manageable’’ sounds
areasonable strategy. However, how can we manage tumor
growthrather than eliminate it? We argue that managing SSS
may be an effective strategy. (STEM CELLS AND DEVELOPMENT
Volume 21,Number 4, 2012, pages 503-506.Mary Ann Liebert, Inc. DOI: 10.1089/scd.2011.0267).
~~
"Your paper is one of the most important discussions
and documented evidence that indirectly support a 19th century view that
the genetic/chromosomal changes found in cancer cells are spurious
manifestation of the malignant state, rather than the cause of their
malignant state."
Cited by Frank Arguello, MD, in his cancer clinical trial company's video clip
at Time 03:32 cited/mentioned our publication - see https://vimeo.com/163936159
By Frank Arguello, MD
Director, Atavistic Chemotherapy Trial
http://www.atavisticchemotherapy.com/
~~
 | ShengwenCalvinLiPhD | 5s |
| At 3:41 minutes (Li): This is the Future of Oncology: The Scientific Quest to Understand and T... youtu.be/KwX43KPbpDY via @YouTube | ||
~~~
When Do You
Give Up on
Treating a Child
With Cancer?
Andrew Levy’s parentsknew that
the rare and deadly cancer in his
blood could not be beaten, so they
began to prepare for the worst. Then
something mysterious happened.
By MELANIE THERNSTROMMAY12, 2016
When Esther and Dan Levy’sson Andrew was 14 months old, he received a diagnosis of a kind of leukemia sorare that their medical team said getting it was like being bitten by a sharkand struck by lightning at the same time.
Leukemia, a cancer ofthose cells in the bone marrow that produce new blood cells, has manyvarieties, but the most common type in children, acute lymphocytic leukemia, islargely curable. Andrew’s cancer, however, a subtype of acute megakaryoblasticleukemia (AMKL), affects only about 45 children a year nationwide and is muchmore difficult to treat. The odds of surviving this type of AMKL are roughlyeven — unless the child is one of a handful who happen to have a particulargenotype, in which case these odds plummet to a mere one in 10. Geneticanalysis revealed that Andrew was in this tiny group.
There was more bad news.Two weeks after the diagnosis, Andrew’s doctor, Norman Lacayo, an oncologist atLucile Packard Children’s Hospital at Stanford University, received an urgentcall from Michael Loken, the president of Hematologics Inc., a Seattle lab thatwas analyzing Andrew’s cells. Loken had recently discovered that a smallpercentage of children with AMKL had a specific phenotype — a pattern ofproteins on the surface of the leukemia cell he called R.A.M. (a former patient’sinitials) — that independently predicted a terrible outcome, with a survivalrate of about one in six. Andrew had this phenotype too.
“Has anyone ever survivedthis kind of cancer?” Dan asked Lacayo. “All I wanted to know is that it wasnot impossible,” Dan recalls. Lacayo said yes, but Dan felt his answer was “foggy.”The truth was that the team couldn’t find a single equivalent case in theliterature.
Beginning on thatDecember morning in 2014 when Esther took Andrew to the E.R., she recalls, shefelt as if they had stepped into a horror movie, the unfolding events bothsurreal and evil. Up to that point, Esther and Dan had led, in her words, “charmedlives — picture perfect.” Only a small subset of people would sincerely saythat nothing truly bad has ever happened to them; before the diagnosis, Estherand Dan say, they were among them. When Andrew got sick, they were in theirmid-30s and energetic, optimistic and extroverted. They had both attendedStanford — Dan majored in industrial engineering, Esther in human biology,
